In the single-arm phase II TROPION-Lung05 trial, Dato-DXd was investigated as a treatment for patients with metastatic NSCLC and at least one or more genomic alterations, including EGFR, ALK, ROS proto oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), b-raf proto-oncogene (BRAF), rearranged during transfection (RET), or mesenchymal–epithelial transition factor (MET) exon 14 skipping, who received up to four prior lines of treatment, including at least one target therapy. Here, ALK is linked to non-small cell lung carcinoma.